CA2193692A1 - Metalloproteinase inhibitors - Google Patents
Metalloproteinase inhibitorsInfo
- Publication number
- CA2193692A1 CA2193692A1 CA002193692A CA2193692A CA2193692A1 CA 2193692 A1 CA2193692 A1 CA 2193692A1 CA 002193692 A CA002193692 A CA 002193692A CA 2193692 A CA2193692 A CA 2193692A CA 2193692 A1 CA2193692 A1 CA 2193692A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- group
- compound
- hydrogen
- butyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Lubricants (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9412514.3 | 1994-06-22 | ||
GB9412514A GB9412514D0 (en) | 1994-06-22 | 1994-06-22 | Metalloproteinase inhibitors |
GB9506107.3 | 1995-03-24 | ||
GBGB9506107.3A GB9506107D0 (en) | 1995-03-24 | 1995-03-24 | Metalloproteinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2193692A1 true CA2193692A1 (en) | 1995-12-28 |
Family
ID=26305102
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002193692A Abandoned CA2193692A1 (en) | 1994-06-22 | 1995-06-22 | Metalloproteinase inhibitors |
CA002193691A Abandoned CA2193691A1 (en) | 1994-06-22 | 1995-06-22 | Metalloproteinase inhibitors |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002193691A Abandoned CA2193691A1 (en) | 1994-06-22 | 1995-06-22 | Metalloproteinase inhibitors |
Country Status (17)
Country | Link |
---|---|
US (4) | US6022898A (zh) |
EP (2) | EP0766665B1 (zh) |
JP (2) | JPH10507158A (zh) |
CN (1) | CN1151157A (zh) |
AT (2) | ATE182581T1 (zh) |
AU (2) | AU690703B2 (zh) |
CA (2) | CA2193692A1 (zh) |
DE (2) | DE69516143T2 (zh) |
DK (2) | DK0766665T3 (zh) |
ES (2) | ES2133785T3 (zh) |
FI (1) | FI965153A0 (zh) |
GB (2) | GB2303850B (zh) |
GR (2) | GR3031143T3 (zh) |
NO (1) | NO965515L (zh) |
NZ (2) | NZ288299A (zh) |
PT (1) | PT766664E (zh) |
WO (2) | WO1995035276A1 (zh) |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5646167A (en) * | 1993-01-06 | 1997-07-08 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamix acids |
US6380366B1 (en) * | 1994-04-28 | 2002-04-30 | Les Laboratoires Aeterna Inc. | Shark cartilage extract:process of making, methods of using and compositions thereof |
DK0766665T3 (da) * | 1994-06-22 | 1999-12-06 | British Biotech Pharm | Metalloproteinaseinhibitorer |
US5817822A (en) * | 1994-06-24 | 1998-10-06 | Novartis Corporation | Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids |
US5863949A (en) * | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
KR980009238A (ko) | 1995-07-28 | 1998-04-30 | 우에노 도시오 | 설포닐아미노산 유도체 |
PT757984E (pt) * | 1995-08-08 | 2003-02-28 | Ono Pharmaceutical Co | Derivados de acido hidroxamico uteis para inibir a gelatinase |
BR9611479B1 (pt) | 1995-11-13 | 2009-01-13 | Ácidos alfa-iminoidroxÂmicos e carboxÍlicos n-substituÍdos cÍclicos e heterocÍclicos. | |
DK0874830T3 (da) * | 1995-12-08 | 2003-04-22 | Agouron Pharma | Metalloproteinaseinhibitor, farmaceutisk præparat indeholdende denne og den farmaceutiske anvendelse samt en fremgangsmåde til fremstilling deraf |
US6500948B1 (en) | 1995-12-08 | 2002-12-31 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof |
TW453995B (en) * | 1995-12-15 | 2001-09-11 | Novartis Ag | Certain alpha-substituted arylsulfonamido acetohydroxamic acids |
CA2242416C (en) * | 1996-01-23 | 2006-03-21 | Shionogi & Co., Ltd. | Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same |
US6919375B1 (en) | 1996-01-23 | 2005-07-19 | Shionogi & Co., Ltd. | Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same |
SK282995B6 (sk) * | 1996-01-23 | 2003-01-09 | Shionogi And Co., Ltd. | Zlúčenina na inhibíciu metaloproteázy a prostriedok s jej obsahom |
US5994351A (en) * | 1998-07-27 | 1999-11-30 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
FR2748026B1 (fr) * | 1996-04-26 | 1998-06-05 | Adir | Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
CA2253342A1 (en) * | 1996-05-17 | 1997-11-27 | Warner-Lambert Company | Biphenylsulfonamide matrix metalloproteinase inhibitors |
DE69731642T2 (de) * | 1996-08-16 | 2005-12-01 | Warner-Lambert Co. Llc | Buttersäure matrix-metalloproteinase-inhibitoren |
SK21499A3 (en) * | 1996-08-23 | 2000-05-16 | Pfizer | Arylsulfonylamino hydroxamic acid derivatives |
DK0923561T3 (da) | 1996-08-28 | 2003-02-24 | Procter & Gamble | Heterocykliske metalloproteaseinhibitorer |
BR9712792A (pt) * | 1996-08-28 | 1999-12-14 | Procter & Gamble | Inibidores de metaloprotease bidentada. |
ES2225983T3 (es) * | 1996-08-28 | 2005-03-16 | THE PROCTER & GAMBLE COMPANY | Inhibidores de metaloproteasas espirociclicos. |
TR199900383T2 (xx) * | 1996-08-28 | 1999-05-21 | The Procter & Gamble Company | 1,3-Diheterosiklik metaloproteaz inhibit�rleri. |
NZ334252A (en) * | 1996-08-28 | 2000-11-24 | Procter & Gamble | Heterocyclic metalloprotease inhibitors |
NZ334258A (en) * | 1996-08-28 | 2000-11-24 | Procter & Gamble | Phosphinic acid amides as matrix metalloprotease inhibitors |
IL129147A0 (en) * | 1996-10-16 | 2000-02-17 | American Cyanamid Co | The preparation and use of ortho-sulfonamide aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
US5929097A (en) * | 1996-10-16 | 1999-07-27 | American Cyanamid Company | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
US5962481A (en) * | 1996-10-16 | 1999-10-05 | American Cyanamid Company | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
US6548524B2 (en) | 1996-10-16 | 2003-04-15 | American Cyanamid Company | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
US5977408A (en) * | 1996-10-16 | 1999-11-02 | American Cyanamid Company | Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
US6228869B1 (en) | 1996-10-16 | 2001-05-08 | American Cyanamid Company | Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
AU4812697A (en) * | 1996-10-22 | 1998-05-15 | Pharmacia & Upjohn Company | Alpha-amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors |
US6174915B1 (en) | 1997-03-25 | 2001-01-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
US6008243A (en) * | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
WO1998018754A1 (en) | 1996-10-28 | 1998-05-07 | Versicor, Inc. | Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof |
US6281245B1 (en) | 1996-10-28 | 2001-08-28 | Versicor, Inc. | Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof |
AU720615B2 (en) * | 1997-01-17 | 2000-06-08 | Pharmacia & Upjohn Company | Bis-sulfonomides hydroxamic acids as MMP inhibitors |
US6376506B1 (en) | 1997-01-23 | 2002-04-23 | Syntex (U.S.A.) Llc | Sulfamide-metalloprotease inhibitors |
ZA98376B (en) * | 1997-01-23 | 1998-07-23 | Hoffmann La Roche | Sulfamide-metalloprotease inhibitors |
US6197791B1 (en) | 1997-02-27 | 2001-03-06 | American Cyanamid Company | N-hdroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
US6172057B1 (en) | 1997-02-27 | 2001-01-09 | American Cyanamid Company | N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
JP2002513408A (ja) | 1997-03-04 | 2002-05-08 | モンサント カンパニー | チオールスルホンアミドヒドロキサム酸化合物 |
GB9706255D0 (en) | 1997-03-26 | 1997-05-14 | Smithkline Beecham Plc | Novel compounds |
US5985900A (en) * | 1997-04-01 | 1999-11-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
CA2285372A1 (en) * | 1997-04-01 | 1998-10-08 | Melwyn A. Abreo | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
US5756545A (en) * | 1997-04-21 | 1998-05-26 | Warner-Lambert Company | Biphenysulfonamide matrix metal alloproteinase inhibitors |
DE19719621A1 (de) | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
WO1998050348A1 (en) * | 1997-05-09 | 1998-11-12 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
DK0877019T3 (da) * | 1997-05-09 | 2002-04-08 | Hoechst Ag | Substituerede diaminocarboxylsyrer |
DE19719817A1 (de) * | 1997-05-13 | 1998-11-19 | Hoechst Ag | Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren |
US6300514B1 (en) | 1997-06-25 | 2001-10-09 | Ono Pharmaceutical Co., Ltd. | Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient |
NZ502274A (en) | 1997-07-22 | 2001-03-30 | Shionogi & Co | The use of a therapeutic or prophylactic agent containing a sulphonamide derivative for treating glomerulopathy |
BR9810841A (pt) | 1997-07-31 | 2001-07-10 | Procter & Gamble | Inibidores de metaloprotease alicìclicos |
ATE217863T1 (de) * | 1997-08-08 | 2002-06-15 | Pfizer Prod Inc | Arylsulfonylaminohydroxamsäurederivate |
US6130220A (en) * | 1997-10-16 | 2000-10-10 | Syntex (Usa) Inc. | Sulfamide-metalloprotease inhibitors |
GB9801690D0 (en) * | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
US6410580B1 (en) | 1998-02-04 | 2002-06-25 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
CN1195735C (zh) | 1998-02-04 | 2005-04-06 | 诺瓦提斯公司 | 抑制使基质退化的金属蛋白酶的磺酰氨基衍生物 |
PL342548A1 (en) * | 1998-02-19 | 2001-06-18 | American Cyanamid Co | N-hydroxy-2-(alkyl-, aryl- or heteroarylsulphanyl-, sulphinyl- or sulphonyl)-3-substituted alkyl-, aryl- or heteroarylamides as inhibitors of matrix metaloproteinases |
US6329418B1 (en) | 1998-04-14 | 2001-12-11 | The Procter & Gamble Company | Substituted pyrrolidine hydroxamate metalloprotease inhibitors |
GB9810464D0 (en) | 1998-05-16 | 1998-07-15 | British Biotech Pharm | Hydroxamic acid derivatives |
ATE227295T1 (de) | 1998-07-16 | 2002-11-15 | Aventis Pharma Gmbh | Phosphin- und phosphonsäurederivate als arzneimittel |
US6107337A (en) * | 1998-08-06 | 2000-08-22 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
DE19851184A1 (de) | 1998-11-06 | 2000-05-11 | Aventis Pharma Gmbh | N-Arylsulfonyl-aminosäure-omega-amide |
US6762178B2 (en) | 1999-01-27 | 2004-07-13 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6946473B2 (en) | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
US6753337B2 (en) | 1999-01-27 | 2004-06-22 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
CN1178915C (zh) | 1999-01-27 | 2004-12-08 | 惠氏控股有限公司 | 含有炔基的异羟肟酸衍生物、其制备及其作为基质金属蛋白酶抑制剂/TNF-α转变酶抑制剂的用途 |
US6200996B1 (en) | 1999-01-27 | 2001-03-13 | American Cyanamid Company | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
US6506936B1 (en) * | 1999-02-25 | 2003-01-14 | Fibrogen, Inc. | N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of c-proteinase and for treating or preventing disorders related to unregulated collagen production |
EP1165501A1 (en) | 1999-03-03 | 2002-01-02 | The Procter & Gamble Company | Alkenyl- and alkynyl-containing metalloprotease inhibitors |
CZ20013155A3 (cs) | 1999-03-03 | 2002-01-16 | The Procter & Gamble Company | Inhibitory metaloproteas |
ATE245152T1 (de) | 1999-03-31 | 2003-08-15 | Pfizer Prod Inc | Dioxocyclopentylhydroxamsäure |
PL355639A1 (en) | 1999-09-10 | 2004-05-04 | Merck & Co, Inc. | Tyrosine kinase inhibitors |
US6696456B1 (en) | 1999-10-14 | 2004-02-24 | The Procter & Gamble Company | Beta disubstituted metalloprotease inhibitors |
MXPA02004985A (es) | 1999-11-26 | 2003-10-14 | Shionogi & Co | Antagonistas del neuropeptido y, y5. |
US6797820B2 (en) * | 1999-12-17 | 2004-09-28 | Vicuron Pharmaceuticals Inc. | Succinate compounds, compositions and methods of use and preparation |
US6465508B1 (en) | 2000-02-25 | 2002-10-15 | Wyeth | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors |
NZ520657A (en) * | 2000-03-21 | 2004-11-26 | Procter & Gamble | Heterocyclic side chain containing, N-substituted metalloprotease inhibitors |
AU2001245863A1 (en) * | 2000-03-21 | 2001-10-03 | The Procter & Gamble Company | Heterocyclic side chain containing metalloprotease inhibitors |
JP2003528082A (ja) * | 2000-03-21 | 2003-09-24 | ザ プロクター アンド ギャンブル カンパニー | ニフッ化酪酸メタロプロテアーゼ阻害物質 |
EP1265887A2 (en) * | 2000-03-21 | 2002-12-18 | The Procter & Gamble Company | Carbocyclic side chain containing metalloprotease inhibitors |
US6495358B1 (en) | 2000-04-19 | 2002-12-17 | Wichita State University | Sulfamide and bis-sulfamide amino acid derivatives as inhibitors of proteolytic enzymes |
EP1309579B1 (en) | 2000-05-30 | 2005-10-12 | Board Of Governors Of Wayne State University | Inhibitors of matrix metalloproteinases |
WO2002072577A2 (en) * | 2001-03-14 | 2002-09-19 | Novartis Ag | Azacycloalkyl substituted acetic acid derivatives for use as mmp inhibitors. |
WO2002092553A1 (en) | 2001-05-11 | 2002-11-21 | Guilford Pharmaceuticals Inc. | Hydroxamic acids and acyl hydroxamines as naaladase inhibitors |
CA2450562A1 (en) | 2001-06-22 | 2003-01-03 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
BR0213736A (pt) | 2001-11-01 | 2004-10-19 | Wyeth Corp | ácidos hidroxâmicos de sulfonamida de arila alênica como metaloproteinase matriz e inibidores de tace |
WO2003104224A1 (en) | 2002-06-10 | 2003-12-18 | Pfizer Inc. | Metabolites of prinomastat and their sythesis |
US6872724B2 (en) | 2002-07-24 | 2005-03-29 | Merck & Co., Inc. | Polymorphs with tyrosine kinase activity |
AU2003304456A1 (en) | 2002-12-23 | 2005-03-16 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors |
JP2006516252A (ja) * | 2002-12-27 | 2006-06-29 | アンジオテック インターナショナル アクツィエン ゲゼルシャフト | コラーゲンおよびmmpiを用いる組成物および方法 |
AU2003300076C1 (en) | 2002-12-30 | 2010-03-04 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
US7576222B2 (en) * | 2004-12-28 | 2009-08-18 | Wyeth | Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase |
US7928127B2 (en) | 2005-05-19 | 2011-04-19 | Notre Dame University | Inhibitors of matrix metallaproteinases |
EA201100187A1 (ru) * | 2008-07-14 | 2011-10-31 | Новартис Аг | Селективные ингибиторы ммр-12 и ммр-13 на основе гидроксамовой кислоты |
WO2011109767A2 (en) | 2010-03-04 | 2011-09-09 | University Of Notre Dame Du Lac | Gelatinase inhibitors and prodrugs |
WO2012038944A1 (en) | 2010-09-24 | 2012-03-29 | Ranbaxy Laboratories Limited | Matrix metalloproteinase inhibitors |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4077998A (en) * | 1975-10-28 | 1978-03-07 | Morton-Norwich Products, Inc. | Phthaloyl amino acid hydroxamic acids |
US4885027A (en) * | 1985-04-05 | 1989-12-05 | Chevron Research Company | Herbicidal arylmethylenesulfonamido-acetamide and thioacetamide derivatives |
DK77487A (da) * | 1986-03-11 | 1987-09-12 | Hoffmann La Roche | Hydroxylaminderivater |
EP0320898A3 (en) * | 1987-12-18 | 1989-08-16 | Schering Corporation | Processes and compounds useful for resolving 1-methyl-3-phenylpropylamine |
GB8827305D0 (en) * | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
DE69108363T2 (de) * | 1990-12-03 | 1995-08-31 | Celltech Ltd | Peptidylderivate. |
US5239113A (en) * | 1991-10-15 | 1993-08-24 | Monsanto Company | Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof |
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5552419A (en) * | 1993-01-06 | 1996-09-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
DK0766665T3 (da) * | 1994-06-22 | 1999-12-06 | British Biotech Pharm | Metalloproteinaseinhibitorer |
US5817822A (en) * | 1994-06-24 | 1998-10-06 | Novartis Corporation | Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids |
CA2253342A1 (en) * | 1996-05-17 | 1997-11-27 | Warner-Lambert Company | Biphenylsulfonamide matrix metalloproteinase inhibitors |
-
1995
- 1995-06-22 DK DK95922639T patent/DK0766665T3/da active
- 1995-06-22 JP JP8501848A patent/JPH10507158A/ja not_active Withdrawn
- 1995-06-22 CN CN95193714A patent/CN1151157A/zh active Pending
- 1995-06-22 NZ NZ288299A patent/NZ288299A/en unknown
- 1995-06-22 ES ES95922639T patent/ES2133785T3/es not_active Expired - Lifetime
- 1995-06-22 US US08/765,146 patent/US6022898A/en not_active Expired - Fee Related
- 1995-06-22 AT AT95922639T patent/ATE182581T1/de not_active IP Right Cessation
- 1995-06-22 CA CA002193692A patent/CA2193692A1/en not_active Abandoned
- 1995-06-22 WO PCT/GB1995/001465 patent/WO1995035276A1/en active IP Right Grant
- 1995-06-22 GB GB9623675A patent/GB2303850B/en not_active Expired - Fee Related
- 1995-06-22 DE DE69516143T patent/DE69516143T2/de not_active Expired - Fee Related
- 1995-06-22 DE DE69511089T patent/DE69511089T2/de not_active Expired - Fee Related
- 1995-06-22 DK DK95922638T patent/DK0766664T3/da active
- 1995-06-22 CA CA002193691A patent/CA2193691A1/en not_active Abandoned
- 1995-06-22 AU AU27466/95A patent/AU690703B2/en not_active Ceased
- 1995-06-22 EP EP95922639A patent/EP0766665B1/en not_active Expired - Lifetime
- 1995-06-22 ES ES95922638T patent/ES2145913T3/es not_active Expired - Lifetime
- 1995-06-22 EP EP95922638A patent/EP0766664B1/en not_active Expired - Lifetime
- 1995-06-22 NZ NZ288298A patent/NZ288298A/xx unknown
- 1995-06-22 WO PCT/GB1995/001464 patent/WO1995035275A1/en active IP Right Grant
- 1995-06-22 AU AU27465/95A patent/AU695507B2/en not_active Ceased
- 1995-06-22 JP JP8501847A patent/JPH10501806A/ja active Pending
- 1995-06-22 PT PT95922638T patent/PT766664E/pt unknown
- 1995-06-22 AT AT95922638T patent/ATE191468T1/de not_active IP Right Cessation
- 1995-06-22 GB GB9623809A patent/GB2303629B/en not_active Expired - Fee Related
- 1995-06-22 US US08/765,140 patent/US5962529A/en not_active Expired - Fee Related
-
1996
- 1996-12-20 FI FI965153A patent/FI965153A0/fi unknown
- 1996-12-20 NO NO965515A patent/NO965515L/no unknown
-
1999
- 1999-02-03 US US09/243,130 patent/US6124332A/en not_active Expired - Fee Related
- 1999-06-30 US US09/343,087 patent/US6124329A/en not_active Expired - Fee Related
- 1999-09-02 GR GR990402229T patent/GR3031143T3/el unknown
-
2000
- 2000-05-18 GR GR20000401133T patent/GR3033446T3/el not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2193692A1 (en) | Metalloproteinase inhibitors | |
EP0740652B1 (en) | Metalloproteinase inhibitors | |
EP0821668B1 (en) | Derivatives of succinamide and their use as metalloproteinase inhibitor | |
EP0777646B1 (en) | Metalloproteinase inhibitors | |
AU711804B2 (en) | Metalloproteinase inhibitors | |
EP0763012B1 (en) | Succinyl hydroxamic acid, n-formyl-n-hydroxy amino carboxylic acid and succinic acid amide derivatives as metalloprotease inhibitors | |
CA2181709A1 (en) | Hydroxamic acid derivatives as metalloproteinase inhibitors | |
US6271262B1 (en) | Metalloproteinase inhibitors | |
US6124333A (en) | Metalloproteinase inhibitors | |
EP0835240B1 (en) | Matrix metalloproteinase inhibitors | |
US5840974A (en) | Metalloproteinase inhibitors | |
CA2238275C (en) | Metalloproteinase inhibitors | |
CA2181570C (en) | Metalloproteinase inhibitors | |
CA2291169A1 (en) | Metalloproteinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |